Overview of medical therapy for gastroesophageal disease

Gastrointestinal Endoscopy Clinics of North America

Volumn 13, Issue 1, 2003, Pages 57-68

  Ramakrishnan, Amarnath ^a   Katz, Philip O ^a  

^a GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ANTIOXIDANT; BACLOFEN; CISAPRIDE; DA 9601; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LOXIGLUMIDE; MORPHINE; NORCISAPRIDE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TEGASEROD; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABLE COLON; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RELAPSE; REVIEW; STOMACH ACID SECRETION;

EID: 0037237739     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5157(02)00105-8     Document Type: Review

References (48)

1. DeVault K, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999;94:1434-42.
2. Hatlebakk JG, Berstad A. Gastroesophageal reflux during three months of therapy with ranitidine in reflux esophagitis. Scand J Gastroenterol 1996;31:954-8.
3. Frislid K, Berstad A. Prolonged influence of a meal on the effect of ranitidine. Scand J Gastroenterol 1984;19:429-32.
4. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996;276:933-8.
5. Bardhan KD, Morris P, Thompson M, et al. Omeprazole in the treatment of erosive esophagitis refractory to high dose of cimetidine and ranitidine. Gut 1990;31:745-9.
6. Huang JQ, Hunt RH. Meta-analysis of comparative trials for healing erosive esophagirls with proton pump inhibitors and H2-receptor antagonists. Gastroenterology 1998;114:A154 [abstract].
7. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive esophagitis. Aliment Pharmacol Ther 1995;9:25-31.
8. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
9. Tutian R, Katz PO, Castell DO. A PPI is a PPI; Lessons from prolonged intra-gastric monitoring. Gastroenterology 2000;118(suppl):A332 [abstract].
10. Richardson P, Hawkey CJ, Stack WA. PPI's: Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998;56:307-35.
11. Caro JJ, Salas M, Ward A. Healing and relapse rates in GERD treated with the newer PPI's lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001;7:998-1017.
12. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249-58.
13. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled study. Am J Gastroenterol 2001;96:656-65.
14. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
15. Johnson DA. Esomeprazole. Todays Therapeutic Trends 2001;19:235-50.
16. Klinkenberg-Knol E, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Gastroenterology 2000;118:661-9.
17. Proton pump inhibitor relabelling for cancer risk is not warranted. FDA reports, November 11, 1996.
18. Vigneri S, Termini R, Leandor G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
19. Marks RD, Richter JE, Rizzo J. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106:907-15.
20. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994;107:1312-8.
21. Lind T, Havelund T, Carlsson O, et al. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
22. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
23. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Euro J Gatsroenterol Hepatol 1998;10:119-24.
24. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994;89:989-91.
25. Lidums I, Holloway R. Motility abnormalities in columnar lined esophagus. Gastroenterol Clin North Am 1997;26:519-31.
26. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997;102:78-88.
27. Ladas SD, Tassios PS, Raptis SA. Selection of patients for successful maintenance treatment of esophagitis with low dose omeprazole: use of 24-hour gastric pH monitoring. Am J Gastroenterol 2000;95:374-80.
28. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100.
29. Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twicedaily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-7.
30. Katz PO, Anderson C, Khoury RM, et al. Gastroesophageal reflux associated with nocturnal acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12:1231-4.
31. Paoletti V, Karvois D, Greski-Rose P, et al. Lansoprazole is superior to omeprazole in increasing both 24-hour and nighttime intragastric pH in "omeprazole failure" GERD patients. Am J Gastroenterol 1997;92:1621 [abstract].
32. Khoury RM, Katz PO, Hammod R, et al. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999;13:675-8.
33. Peghini PL, Katz PO, Castell DO, et al. Ranitidine controls nocturnal acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
34. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal acid breakthrough. Gastroenterology 2002;122:625-32.
35. Xue S, Katz PO, Banerjee P, et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on PPIs. Aliment Pharmacol Ther 2001;15:1351-6.
36. Dent J, Brun J, Fendrick AM, et al. on behalf of the Genval Workshop Group. An evidence based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16.
37. Howden CW, Henning JM, Huang B, et al. Management of heartburn in a large randomized community-based study: Comparison of four therapeutic strategies. Am J Gastroenterol 2001;96:1704-10.
38. Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with GERD? A critical review of the literature. Chest 1998;114:275-83.
39. Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppression therapy improves asthma outcome. Am J Med 1996;100:395-405.
40. Levin TR, Sperling RM, McQuaid KR. Omeprazole improves peak expiratory flow rate and quality of life in asthmatics in gastroesophageal reflux. Am J Gastroenterol 1998;93:1060-3.
41. Kiljander TO, Salomaa ER, Hietanen EK, et al. Gastroesophageal reflux in asthmatics: a double blind, placebo-controlled crossover study with omeprazole. Chest 1999;116:1257-64.
42. Achem S, Kolts B, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997;42:2138-45.
43. El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: A placebo controlled trial. Am J Gastroenterol 2001;96:979-83.
44. Ours TM, Kavaru MS, Schilz RJ, et al. A prospective evaluation of esophageal testing and a double blind randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999;94:3131-8.
45. Kiljander TO, Salomaa ERM, Hietanen EK, et al. Chronic cough and gastroesophageal reflux: a double blind placebo controlled study with omeprazole. Eur Respir J 2000;16:633-8.
46. Zhang Q, Lehmann A, Rigda R, et al. Control of TLOSRs and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2000;50:19-24.
47. Oh TY, Lee JS, Ahn BO, et al. Oxidative stress is more important than acid in the pathogenesis of reflux esophagitis in rats. Gut 2001;49:364-71.
48. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5 year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001;192:172-81.